Atopic dermatitis (AD) highlights from the 2025 American Academy of Dermatology Annual Meeting include phase 3 trial results on rocatinlimab and delgocitinib, findings on tapinarof 1% cream, and early dosing findings on a new JAK1/TYK2 inhibitor, as reported by Dr Lindsey Strowd of Wake Forest School of Medicine in Winston-Salem, North Carolina.
Dr Strowd begins with results from the phase 3 ROCKET HORIZON trial, which showed that rocatinlimab significantly improved AD symptoms by targeting the OX40 receptor. The study found that 20% of the patients in the rocatinlimab arm vs 7% on placebo achieved an investigator’s global assessment score of 0 or 1 at the study endpoint.
Next, Dr Strowd reviews the DELTA 1 and DELTA 2 phase 3 trials evaluating delgocitinib in patients with moderate to severe hand eczema. The results showed that 20%-30% of patients taking delgocitinib achieved an overall score of clear or almost clear, compared with 7%-10% of patients receiving placebo.
She then discusses the ADORING 3 trial examining patients aged 2 years or older who were using tapinarof 1% cream for mild to moderate AD. After discontinuation of tapinarof, patients maintained low-level disease activity for an average of 80 consecutive days.
Dr Strowd also discusses a 12-week phase 2 dose-ranging study of an oral JAK1/TYK2 inhibitor, which showed that 80% of the patients receiving 10 mg and 20 mg twice daily achieved an EASI-75 response at the end of 12 weeks. The medication also showed quality-of-life improvement.
